Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
复制标题
DOI：
10.3892/ol.2020.11274
复制
发表时间：
2020-03-01
期刊：
影响因子：
2.9
通讯作者：
Yang, Liang
中科院分区：
文献类型：
--
作者：
Jiang, Weihua;Wang, Xiaowen;Yang, Liang
为了研究丝裂原激活蛋白激酶（MAPK）和表皮生长因子受体（EGFR）在三阴性乳腺癌（TNBC）中的表达和临床意义，总共检查了300个TNBC和120对癌旁组织。采用免疫组化法测定MAPK和EGFR的表达水平，并采用Cramer's V检验评估MAPK和EGFR表达的相关性。还使用chi(2)检验评估了MAPK和EGFR表达以及各种临床病理学变量（例如淋巴结转移、临床分期、复发和转移）之间的关联。 TNBC 组织中 MAPK 和 EGFR 的表达水平显着高于配对的癌旁组织。此外，TNBC 组织中 MAPK 表达与 EGFR 表达相关。淋巴结转移、临床分期晚期、肿瘤复发转移患者中MAPK、EGFR阳性表达率高于无淋巴结转移患者。 TNBC组织中MAPK和EGFR阳性表达的患者比不表达的患者预后更差，总生存时间更短。综上所述，MAPK和EGFR的表达与TNBC的肿瘤侵袭和转移密切相关，因此可作为TNBC患者预后不良的指标。
To investigate the expression and clinical significance of mitogen-activated protein kinase (MAPK) and epidermal growth factor receptor (EGFR) in triple-negative breast cancer (TNBC), a total of 300 TNBC and 120 paired paracancerous tissues were examined. Immunohistochemistry was conducted to determine the expression levels of MAPK and EGFR, and the correlation between MAPK and EGFR expression was evaluated using Cramer's V test. The association between MAPK and EGFR expression, and various clinicopathological variables (such as lymph node metastasis, clinical stage, recurrence and metastasis) was also evaluated, using the chi(2) test. MAPK and EGFR expression levels in TNBC tissues were significantly higher than in the paired paracancerous tissues. Moreover, MAPK expression was associated with that of EGFR in TNBC tissues. The positive expression rates of MAPK and EGFR in patients with lymph node metastasis, advanced clinical stage, tumor recurrence and metastasis were higher than those without. Patients with positive expression of MAPK and EGFR in TNBC tissues had poorer prognoses and lower overall survival times than those without expression. In summary, the expression of MAPK and EGFR is closely associated with tumor invasion and the metastasis of TNBC, and may therefore be used as an indicator of poor prognosis in patients with TNBC.